GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties - AnaptysBio ( NASDAQ:ANAB ) , GSK ( NYSE:GSK )
GSK plc ( NYSE:GSK ) subsidiary, Tesaro Inc., has initiated litigation against AnaptysBio, Inc. ( NASDAQ:ANAB ) in the Delaware Chancery Court. GSK acquired Tesaro in December 2018 for approximately $5.1 billion ( 4.0 billion British pounds )
Elastic, Veeva Systems, HIVE Digital And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Albemarle ( NYSE:ALB ) , American Bitcoin ( NASDAQ:ABTC )
U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Friday. Shares of Elastic NV ( NYSE:ESTC ) fell sharply in pre-market trading after reporting second-quarter results. Elastic reported quarterly adjusted earnings of 64 cents per share, beating the ...
Anaptys Announces $100 Million Stock Repurchase Plan - AnaptysBio ( NASDAQ:ANAB )
SAN DIEGO, Nov. 21, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( NASDAQ:ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized an amended Stock Repurchase Plan under which the Company ...
Anaptys Announces $100 Million Stock Repurchase Plan
SAN DIEGO, Nov. 21, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized an amended Stock Repurchase Plan under which the Company ...
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
SAN DIEGO, Nov. 21, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced it has filed a Verified Complaint in Delaware Chancery Court, requesting a court declaration that TESARO, ...
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary - AnaptysBio ( NASDAQ:ANAB )
SAN DIEGO, Nov. 21, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( NASDAQ:ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced it has filed a Verified Complaint in Delaware Chancery Court, requesting a court declaration that TESARO, ...
Why Is AnaptysBio Stock Trading Lower Today? - AnaptysBio ( NASDAQ:ANAB )
AnaptysBio Inc. ( NASDAQ:ANAB ) on Monday released data from the Phase 2 trial of rosnilimab for moderate-to-severe ulcerative colitis. Investigational rosnilimab was safe and well-tolerated.
Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis
SAN DIEGO, Nov. 10, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that investigational rosnilimab was safe and well tolerated but did not meet the primary endpoint of ...
AnaptysBio, Inc. ( ANAB ) Surpasses Q3 Earnings and Revenue Estimates
AnaptysBio (ANAB) delivered earnings and revenue surprises of +149.06% and +145.36%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
SAN DIEGO, Nov. 04, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the third quarter ended September 30, 2025, and provided a business update.
Anaptys Announces Participation in November Investor Conferences
SAN DIEGO, Nov. 04, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its ...
Anaptys Announces Participation in November Investor Conferences - AnaptysBio ( NASDAQ:ANAB )
SAN DIEGO, Nov. 04, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( NASDAQ:ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its ...
Pacira ( PCRX ) Expected to Beat Earnings Estimates: Should You Buy?
Pacira (PCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation
SAN DIEGO, Oct. 29, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced late-breaking data from the robust, global 424-patient Phase 2b trial of rosnilimab, a selective and ...
AnaptysBio, Inc. ( ANAB ) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
AnaptysBio (ANAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025
SAN DIEGO, Oct. 13, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that complete data from the Phase 2b trial of rosnilimab, a pathogenic T cell depleter, in ...
AnaptysBio Charts Path To Split Into Two Companies By 2026 - AnaptysBio ( NASDAQ:ANAB )
AnaptysBio, Inc. ( NASDAQ:ANAB ) announced on Tuesday that it plans to explore separating its business into two independent, publicly traded companies.
United Natural Foods Posts Upbeat Results, Joins AnaptysBio, Semtech, UiPath And Other Big Stocks Moving Higher On Tuesday - Robo.ai ( NASDAQ:AIIO ) , Adaptive Biotechnologies ( NASDAQ:ADPT )
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Tuesday. Shares of United Natural Foods, Inc. ( NYSE:UNFI ) rose sharply during Tuesday's session after the company reported better-than-expected fourth-quarter EPS and sales and issued FY26 EPS guidance above ...
Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026
SAN DIEGO, Sept. 29, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced today that its Board of Directors approved plans to explore separating its business into two independent, ...
Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14
SAN DIEGO, Sept. 29, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will host a virtual investor event on ANB033, its CD122 antagonist, at 4:30pm ET / 1:30pm PT on ...
Anaptys Announces Participation in September Investor Conferences
SAN DIEGO, Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its ...
Anaptys Announces Participation in September Investor Conferences - AnaptysBio ( NASDAQ:ANAB )
SAN DIEGO, Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ANAB, a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive ...
AnaptysBio ( ANAB ) Q2 Revenue Jumps 103%
AnaptysBio ( NASDAQ:ANAB ) , a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases, released its Q2 2025 earnings on August 6, 2025. The company reported $22.3 million in collaboration revenue in Q2 2025, more than doubling ...
AnaptysBio, Inc. ( ANAB ) Reports Q2 Loss, Tops Revenue Estimates
AnaptysBio (ANAB) delivered earnings and revenue surprises of +10.67% and +36.82%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update
SAN DIEGO, Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the second quarter ended June 30, 2025, and provided a business update.
AC Immune ( ACIU ) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors - Avalo Therapeutics ( NASDAQ:AVTX )
WAYNE, Pa., June 18, 2025 ( GLOBE NEWSWIRE ) -- Avalo Therapeutics, Inc. AVTX, a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Rita Jain, M.D. to its Board of Directors.
AnaptysBio Upgraded After RA Drug Matches Top Therapies In Phase 2 Trial - AnaptysBio ( NASDAQ:ANAB )
69% of rosnilimab patients achieved low disease activity by Week 14; 83% remained in LDA at Week 34. All doses showed statistically significant ACR20 and DAS-28 CRP reductions at Week 12 vs placebo. Get access to the leaderboards pointing to tomorrow's biggest stock movers. AnaptysBio, Inc.
Crude Oil Falls Over 1%; ISM Services PMI Tumbles In May - AnaptysBio ( NASDAQ:ANAB ) , Asana ( NYSE:ASAN )
U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining more than 50 points on Wednesday. The Dow traded up 0.09% to 42,558.84 while the NASDAQ rose 0.31% to 19,459.23. The S&P 500 also rose, gaining, 0.19% to 5,981.93. Communication services shares jumped by ...
This Snowflake Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - AnaptysBio ( NASDAQ:ANAB ) , Blueprint Medicines ( NASDAQ:BPMC )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. HC Wainwright & Co. analyst Emily Bodnar upgraded the rating for AnaptysBio, Inc.
Heico, Monro, Abercrombie & Fitch, Joby Aviation And Other Big Stocks Moving Higher On Wednesday - AnaptysBio ( NASDAQ:ANAB ) , Abercrombie & Fitch ( NYSE:ANF )
U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Wednesday. Shares of HEICO Corporation HEI rose sharply during Wednesday's session following better-than-expected quarterly results. Heico reported quarterly earnings of $1.12 per share which beat the analyst ...
Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025
SAN DIEGO, May 27, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review updated data from the global Phase 2b RENOIR clinical trial of ...
Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025 - AnaptysBio ( NASDAQ:ANAB )
SAN DIEGO, May 27, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc.
CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer - CytoDyn ( OTC:CYDY )
VANCOUVER, Washington, May 06, 2025 ( GLOBE NEWSWIRE ) -- CytoDyn Inc. CYDY ( "CytoDyn" or the "Company" ) , a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that Robert E.
AnaptysBio, Inc. ( ANAB ) Reports Q1 Loss, Tops Revenue Estimates
AnaptysBio (ANAB) delivered earnings and revenue surprises of 1.54% and 52.31%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update
SAN DIEGO, May 05, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the first quarter ended March 31, 2025, and provided a business update.
AnaptysBio ( ANAB ) Moves 9.5% Higher: Will This Strength Last?
AnaptysBio (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Crude Oil Gains 1%; US Composite PMI Surges In March - AnaptysBio ( NASDAQ:ANAB ) , AZEK Co ( NYSE:AZEK )
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 350 points on Monday. The Dow traded up 1.35% to 42,551.10 while the NASDAQ climbed 2.08% to 18,119.66. The S&P 500 also rose, gaining, 1.66% to 5,761.78. Consumer discretionary shares jumped by 3.2% on ...
Intuitive Machines Posts Q4 Results, Joins Tesla, AnaptysBio, Coherent And Other Big Stocks Moving Higher On Monday - AnaptysBio ( NASDAQ:ANAB ) , AZEK Co ( NYSE:AZEK )
U.S. stocks were higher, with the Dow Jones index gaining around 450 points on Monday. Shares of Intuitive Machines, Inc. LUNR rose sharply during Monday's session following fourth-quarter results.
Anaptys Announces Stock Repurchase Plan
SAN DIEGO, March 24, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may ...
Anaptys Announces Stock Repurchase Plan - AnaptysBio ( NASDAQ:ANAB )
SAN DIEGO, March 24, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ANAB, a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to ...
UiPath Posts Weak Revenue, Joins SentinelOne, American Eagle And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - AnaptysBio ( NASDAQ:ANAB ) , American Eagle Outfitters ( NYSE:AEO )
U.S. stock futures were lower this morning, with the Dow futures falling around 0.1% on Thursday. Shares of UiPath Inc. PATH fell sharply in today's pre-market trading after the company reported a fourth-quarter revenue miss and issued first-quarter revenue guidance below estimates.
Why Intel Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - Aditxt ( NASDAQ:ADTX ) , American Eagle Outfitters ( NYSE:AEO )
Shares of Intel Corporation INTC rose sharply in today's pre-market trading after the company announced a new chief executive officer. The company said its board of directors has appointed Lip-Bu Tan, a former member of Intel's board of directors, as chief executive officer, effective March 18.
AnaptysBio, Inc. ( ANAB ) Reports Q4 Loss, Tops Revenue Estimates
AnaptysBio (ANAB) delivered earnings and revenue surprises of 55.28% and 324.09%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Astrana Health, Inc. ( ASTH ) Reports Q4 Loss, Tops Revenue Estimates
Astrana Health, Inc. (ASTH) delivered earnings and revenue surprises of -266.67% and 5.42%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
SAN DIEGO, Feb. 27, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided a business ...
Anaptys Announces Participation in March Investor Conferences
SAN DIEGO, Feb. 27, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ( Nasdaq: ANAB ) , a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its ...
Anaptys Announces Participation in March Investor Conferences - AnaptysBio ( NASDAQ:ANAB )
SAN DIEGO, Feb. 27, 2025 ( GLOBE NEWSWIRE ) -- AnaptysBio, Inc. ANAB, a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive ...
Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors
VANCOUVER, British Columbia, Feb. 18, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc. ( Nasdaq: ZYME ) , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, ...
Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors - Zymeworks ( NASDAQ:ZYME )
VANCOUVER, British Columbia, Feb. 18, 2025 ( GLOBE NEWSWIRE ) -- Zymeworks Inc.
